30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT00680017 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia
Kidney Disease

Interventions

DRUG: ABT-335 plus rosuvastatin
DRUG: Rosuvastatin

Sponsor

AstraZeneca